BeiGene SSE – BeiGene Shanghai Investors

Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo.

All Documents



Press Releases

Jun 21, 2022
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab    read more...
Jun 13, 2022
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets    read more...
Jun 13, 2022
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL    read more...
Press Releases

Thank you for your interest in Beigene, Ltd ! You will receive an email shortly. Please confirm your email address by clicking the link inside.

Back to the form